Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
Myriad Genetics reported Q2 2026 revenue of $190.7 million, down 11% year-over-year, citing volume declines in Prenatal Health and increased payer friction impacting reimbursement rates. The company revised its full-year 2026 revenue guidance down to $770-$790 million and suspended its Adjusted EBITDA guidance as it launches a strategic review called 'Ascend' to improve efficiency and scalability.
Key figures
- Revenue
- $190.7 million
- Guidance
- FY2026 Revenue $770-$790 million (revised lower); Suspended Adjusted EBITDA guidance
- Revenue Yoy
- -11%
- Test volume
- 379000
- Cash and equivalents
- 115.2
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.